R2 readies virtual colonoscopy CAD for FDA approval
R2 Technology has unveiled at the RSNA meeting a robust version of computer-aided detection technology programmed to find colon polyps. The company plans to take this latest iteration of CAD, first shown at the 2002 RSNA meeting, to the FDA in next year.
R2 Technology has unveiled at the RSNA meeting a robust version of computer-aided detection technology programmed to find colon polyps. The company plans to take this latest iteration of CAD, first shown at the 2002 RSNA meeting, to the FDA in next year.
"This is going to be one of the hottest CAD areas because it will open up virtual colonoscopy as a modality itself," said R2 CEO Michael Klein.
One reason virtual colonoscopy has not taken off is the difficulty physicians have reading the images, according to Klein. Another reason is that patients still must evacuate the colon before the examination. CAD could help alleviate both problems
CAD for colonoscopy has the potential to speed up the exam and eliminate the need to prep the bowel. R2's virtual colonoscopy system can electronically remove stool from colon scans by distinguishing differences in density between fecal material and polyps.
The system also simplifies interpretation of virtual colonoscopy scans. By taking radiologists directly to areas where suspicious nodules may be present, CAD may trim interpretation time down to a few minutes, Klein said.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
